An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma
Publication in refereed journal

Times Cited
Web of Science79WOS source URL (as at 14/10/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractPurpose: Persistently elevated posttreatment plasma EBV DNA is a robust predictor of relapse in nasopharyngeal carcinoma (NPC). However, assay standardization is necessary for use in biomarker-driven trials. We conducted a study to harmonize the method between four centers with expertise in EBV DNA quantitation.
All Author(s) ListLe QT, Zhang Q, Cao HB, Cheng AJ, Pinsky BA, Hong RL, Chang JT, Wang CW, Tsao KC, Lo YMD, Lee N, Ang KK, Chan ATC, Chan KCA
Journal nameClinical Cancer Research
Volume Number19
Issue Number8
PublisherAmerican Association for Cancer Research
Pages2208 - 2215
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-15-10 at 00:01